Related Experiment Video
Updated: Apr 25, 2026
08:24
A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
Published on: November 25, 2022
2.2K
Modulation of alpha-synuclein toxicity in yeast using a novel microfluidic-based gradient generator.
João Tiago S Fernandes1, Sandra Tenreiro, Andreia Gameiro
1INESC Microsistemas e Nanotecnologias and IN - Institute of Nanoscience and Nanotechnology, R. Alves Redol, 9, 1000-029, Lisbon, Portugal.
Lab on a Chip
|August 29, 2014
Summary
Researchers developed a microfluidic device to study alpha-synuclein (aSyn) aggregation in yeast. Iron and antioxidants significantly impact aSyn inclusion formation, revealing new insights into Parkinson's disease mechanisms.
Area of Science:
- Neuroscience
- Biochemistry
- Biotechnology
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder linked to alpha-synuclein (aSyn) aggregation.
- The cellular impact of aSyn aggregation, a hallmark of Lewy bodies, remains unclear.
Purpose of the Study:
- To develop a high-throughput, single-cell resolution platform for studying aSyn biology.
- To investigate the effects of environmental factors on aSyn production and aggregation in Saccharomyces cerevisiae.
Main Methods:
- Utilized an elastomeric microfluidic device with a chemical gradient generator and cell traps.
- Monitored aSyn expression and aggregation using aSyn-GFP fusion in single yeast cells.
- Applied galactose (GAL) gradients for aSyn expression modulation and FeCl3/ascorbic acid gradients for environmental factor studies.
Main Results:
- Observed significant variability in single-cell responses to stimuli.
- FeCl3 exposure dramatically increased aSyn inclusions from 27% to 96%.
- Ascorbic acid (antioxidant) significantly reduced aSyn inclusions from 87% to 37%.
Conclusions:
- The developed microfluidic device enables powerful, high-throughput, single-cell analysis of aSyn biology.
- Environmental factors like iron and antioxidants critically influence aSyn aggregation.
- Findings provide new avenues for understanding PD pathogenesis and potential therapeutic targets.
